The Tisch Cancer Institute at Mount Sinai has been awarded a $1.9 million grant by NCI for a study that will explore the mechanisms that enable tumor cells to spread from their original site but remain dormant for some time before becoming metastatic and threatening the lives of patients.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
